Immatics N.V.

IMTX

NL0015285941

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 02:46:11 2025-06-23 pm EDT			5-day change	1st Jan Change
5.325 ^USD	-5.08%		-11.64%	-24.19%

May. 31	Immatics IMA203 PRame Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-Tumor Activity and Durability in Patients with Metastatic Melanoma	CI
May. 28	Deutsche Bank Initiates Coverage on Immatics With Buy Rating, $10 Price Target	MT

Immatics: Q1 Earnings Snapshot

Published on 05/13/2025 at 07:13

TUBINGEN, Germany (AP) — TUBINGEN, Germany (AP) — Immatics N.V. (IMTX) on Tuesday reported a loss of $41.9 million in its first quarter.

The Tubingen, Germany-based company said it had a loss of 35 cents per share.

The company posted revenue of $19.5 million in the period.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on IMTX at https://www.zacks.com/ap/IMTX

For copyright information, check with the distributor of this item, STATS Perform dba Automated Insights. , source Associated Press News

Latest news about Immatics N.V.

Immatics IMA203 PRame Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-Tumor Activity and Durability in Patients with Metastatic Melanoma	May. 31	CI
Deutsche Bank Initiates Coverage on Immatics With Buy Rating, $10 Price Target	May. 28	MT
Immatics Announces First Quarter 2025 Financial Results	May. 13	RE
Immatics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 13	CI
Immatics N.V. Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-Cell Therapy At 2025 Asco Annual Meeting	Apr. 23	CI
Immatics N.V. Reports Earnings Results for the Full Year Ended December 31, 2024	Mar. 27	CI
Top Premarket Decliners	Mar. 25	MT
Top Premarket Decliners	Mar. 24	MT
BofA Securities Adjusts Price Target on Immatics to $13 From $15, Maintains Buy Rating	Jan. 07	MT
Certain Ordinary Shares of Immatics N.V. are subject to a Lock-Up Agreement Ending on 10-DEC-2024.	Dec. 09	CI
Certain Warrants of Immatics N.V. are subject to a Lock-Up Agreement Ending on 10-DEC-2024.	Dec. 09	CI
Certain Options of Immatics N.V. are subject to a Lock-Up Agreement Ending on 10-DEC-2024.	Dec. 09	CI
Immatics N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 18	CI
Exchange-Traded Funds Down, Equity Futures Mixed Pre-Bell Friday as Investors Gear Up for Earnings Season	24-10-11	MT
Immatics Prices $150 Millon Public Offering	24-10-11	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	24-10-10	MT
Immatics Says ACTengine IMA203 Shows 54% Objective Response Rate in Updated Melanoma Trial Data	24-10-10	MT
Immatics Launches $150 Million Public Offering of Ordinary Shares	24-10-10	MT
Immatics Announces Updated Phase 1b Clinical Data on ACTengine IMA203 TCR-T Targeting PRame in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial	24-10-10	CI
Piper Sandler Initiates Immatics With Overweight Rating, $19 Price Target	24-10-07	MT
Sector Update: Health Care Stocks Flat to Higher Premarket Monday	24-09-16	MT
Immatics Ends Collaboration With Bristol-Myers to Co-Develop IMA401 Targeting Melanoma-Associated Antigen	24-09-16	MT
Immatics N.V. Provides Proof-Of-Concept Clinical Data from Its Ongoing Phase 1 Trial with TCER Bispecific Molecule TCER® Ima401	24-09-16	CI
Immatics' Q2 Loss Narrows, Revenue Declines	24-08-13	MT
Immatics N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	24-08-13	CI

Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.

Employees

646

Sector

Biotechnology & Medical Research

Calendar

Aug. 11 - Q2 2025 Earnings Release (Projected)

More about the company